Probiotic as a Novel Treatment Strategy Against Liver Disease.
Context: A symbiotic relationship between the liver and intestinal tract enables the healthy status of both organs. Microflora resident in intestinal lumen plays a significant role in hepatocytes function. Alterations to the type and amount of microorganisms that live in the intestinal tract can res...
| Publicado en: | Hepatitis Monthly Vol. 13; no. 2; pp. 1 - 13 |
|---|---|
| Autores principales: | , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Kowsar Medical Publishing Company
Feb2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=90528299&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 90528299 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1735143X 780O jtl: Hepatitis Monthly issn: 1735143X maglogo: N pubinfo: dt: Feb2013 vid: 13 iid: 2 pid: 78170 pub: Kowsar Medical Publishing Company place: , <Blank> artinfo: ui: 90528299 104234476 104234476 10.5812/hepatmon.7521 90528299 ppf: 1 ppct: 12 formats: tig: atl: Probiotic as a Novel Treatment Strategy Against Liver Disease. aug: au: Imani Fooladi, Abbas Ali Hosseini, Hamideh Mahmoodzadeh Nourani, Mohammad Reza Khani, Soghra Alavian, Seyed Moayed affil: Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran sug: subj: Liver Diseases Prevention and Control Probiotics Therapeutic Use Human Iran Academic Medical Centers Fatty Liver Prevention and Control Liver Cirrhosis Prevention and Control Hepatic Encephalopathy Prevention and Control Hepatitis Prevention and Control Carcinoma, Hepatocellular Prevention and Control Cholangitis, Sclerosing Prevention and Control ab: Context: A symbiotic relationship between the liver and intestinal tract enables the healthy status of both organs. Microflora resident in intestinal lumen plays a significant role in hepatocytes function. Alterations to the type and amount of microorganisms that live in the intestinal tract can result in serious and harmful liver dysfunctions such as cirrhosis, nonalcoholic fatty liver disease, alcoholic liver disease, and hepatic encephalopathy. An increased number of pathogens, especially enterobacteriaceae, enterococci, and streptococci species causes the elevation of intestinal permeability and bacterial translocation. The presence of high levels of lipopolysaccharide (LPS) and bacterial substances in the blood result in a portal hypertension and ensuing hepatocytes damage. Several methods including the usage of antibiotics, prebiotics, and probiotics can be used to prevent the overgrowth of pathogens. Compared to prebiotic and antibiotic therapy, probiotics strains are a safer and less expensive therapy. Probiotics are "live microorganisms (according to the FAO/WHO) which when administered in adequate amounts confer a health benefit on the host”. Evidence Acquisitions: Data from numerous preclinical and clinical trials allows for control of the flora bacteria quantity, decreases incompounds derived from bacteria, and lowers proinflammatory production such as TNF-α, IL-6 and IFN-γ via down-regulation of the nuclear factor kappa B (NF-κ B). Results: On the other hand, probiotic can reduce the urease activity of bacterial microflora. Furthermore, probiotic decreases fecal pH value and reduces ammonia adsorption. In addition, the serum level of liver enzymes and other substances synthesized by the liver are modulated subsequent to probiotic consumption. Conclusions: According to our knowledge, Probiotic therapy as a safe, inexpensive and a noninvasive strategy can reduce pathophysiological symptoms and improve different types of liver diseases without side effects pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|